市場調査レポート

商品コード

1790280

ポイントオブケア分子診断市場規模、シェア、動向分析レポート：用途別、技術別、検査場所別、最終用途別、地域別、セグメント予測、2025年～2033年

Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033

出版日: 2025年07月28日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 884,943円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,033,673円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,331,133円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.73円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ポイントオブケア分子診断市場概要

世界のポイントオブケア分子診断市場規模は2024年に82億2,000万米ドルと推定され、2033年には144億7,000万米ドルに達すると予測され、2025～2033年のCAGRは6.52%で成長します。この市場は、患者の近くで実施される迅速かつ正確な分子検査に重点を置き、タイムリーな臨床判断を可能にします。これらのプラットフォームは、特に感染症検出、呼吸器疾患、性感染症など、さまざまな用途で使用されています。

市場成長の原動力は、特に資源が限られた環境や救急医療環境における分散型検査に対する需要の高まりです。感染症負担の増大と迅速な納期の必要性により、ポイントオブケア分子技術の採用が拡大しています。マイクロ流体工学、等温増幅法、携帯型PCRシステムなどの技術的進歩により、これらの診断法の精度と使いやすさが向上しています。さらに、パンデミック後のヘルスケアの優先事項として、迅速な対応検査が重視されており、市場の拡大をさらに後押ししています。

さらに、プライマリケアの現場におけるPOC分子診断は、単純なグルコース検査から複雑な凝固検査まで多岐にわたります。いくつかのクリニックでは、専門家が従来型ラボ検査からPOC検査に切り替えており、検体の準備や輸送中の遅延を回避することで、さらなる検査が必要かどうかの判断にかかる時間を短縮するのに役立っています。POC分子診断のその他の利点は、結果が迅速に得られること、コストが低いこと、転帰が良好であることです。Point of Care分子診断産業は、POCTの医療的・組織的問題や経済的利点など様々な問題に対する意識の高まりにより、米国や欧州の諸国を中心にここ数年で急成長しています。

加齢は、いくつかの環境要因や遺伝的要因の相互作用の影響を受け、がん発症の最も重大な危険因子として特徴づけられます。米国国立がんラボのSurveillance Epidemiology and End Results（SEER）データベースによると、女性の38％、男性の43％が一生の間にがんに罹患すると推定されています。新規のがん症例の3分の2近くが65歳以上で診断されており、加齢によってがんにかかりやすくなることが浮き彫りになっています。分子診断学は、がん、感染症、心血管疾患の管理に多大な影響を与えるため、重要な役割を果たします。従って、公衆衛生のモニタリングと発見には不可欠です。したがって、高齢者の増加が市場成長の原動力になると予想されます。

さらに、市場関係者は市場機会を生かすため、新規POC検査製品の開発に継続的に取り組んでいます。例えば、2023年2月、Huwel Lifesciencesは、ウイルスタイプを検査するポータブルRT-PCR装置を設計しました。同社は、この検査にかかる時間は約30分で、血液や胃腸のサンプルを使って呼吸器感染症やその他の感染症の検出に使用できると主張しています。さらに、2023年4月、Curative, Inc.はSensible Diagnosticsのスピンオフを発表し、高精度で10分以内に結果を提供する新しいPOC PCR検査プラットフォームの商業化に注力しています。

市場セグメンテーションと範囲
市場系統の展望
- 親市場の展望
- 関連/補助市場展望
市場力学
市場促進要因
- 迅速かつ分散型の検査に対する需要の高まり
- 感染症の蔓延率の上昇
- 分子プラットフォームにおける技術の進歩
市場抑制要因分析
- 分子POCデバイスと消耗品の高コスト
- 規制と品質保証の課題
ビジネス環境分析
- SWOT分析、要因別（政治・法律、経済技術）
- ポーターのファイブフォース分析
- COVID-19の影響分析

第4章技術ビジネス分析

ポイントオブケア分子診断市場：技術変動分析
PCRベース
- 市場、2021～2033年
遺伝子配列による
- 市場、2021～2033年
ハイブリッド化ベース
- 市場、2021～2033年
マイクロアレイベース
- 市場、2021～2033年

第5章用途ビジネス分析

ポイントオブケア分子診断市場：用途変動分析
感染症
- 感染症市場、2021～2033年
- HIV POC
- クロストリジウム・ディフィシルPOC
- HBV POC
- 肺炎または連鎖球菌関連感染症
- 呼吸器合胞体ウイルス（RSV）POC
- HPV POC
- インフルエンザ/インフルエンザPOC
- HCV POC
- MRSA POC
- 結核と薬剤耐性結核のPOC
- HSV POC
- その他の感染症
腫瘍学
- 市場、2021～2033年
血液学
- 市場、2021～2033年
出生前検査
- 市場、2021～2033年
内分泌学
- 市場、2021～2033年
その他
- 市場、2021～2033年

第6章検査場所ビジネス分析

ポイントオブケア分子診断市場：検査場所変動分析
OTC
- 市場、2021～2033年
POC
- 市場、2021～2033年

第7章最終用途ビジネス分析

ポイントオブケア分子診断市場：最終用途変動分析
分散型ラボ
- 市場、2021～2033年
病院
- 市場、2021～2033年
在宅医療
- 市場、2021～2033年
介護付きヘルスケア施設
- 市場、2021～2033年
その他
- 市場、2021～2033年

第8章地域ビジネス分析

地域別POC分子診断市場シェア、2024年と2033年
北米
- 北米のポイントオブケア分子診断市場、2021～2033年
- 米国
- カナダ
- メキシコ
欧州
- 欧州のポイントオブケア分子診断市場、2021～2033年
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- デンマーク
- スウェーデン
- ノルウェー
アジア太平洋
- アジア太平洋のポイントオブケア分子診断市場、2021～2033年
- 日本
- 中国
- インド
- 韓国
- オーストラリア
- タイ
ラテンアメリカ
- ラテンアメリカのポイントオブケア分子診断市場、2021～2033年
- ブラジル
- アルゼンチン
中東・アフリカ
- 中東・アフリカのポイントオブケア分子診断市場、2021～2033年
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

参入企業概要
参入企業
- マーケットリーダー
- ポイントオブケア分子診断市場シェア分析（2023年）
- 企業プロファイル
- 戦略マッピング

図表

List of Tables

Table 1. Point-of-care Molecular Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
Table 2. Global Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 3. Global Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 4. Global Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 5. Global Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 6. Global Point-of-care Molecular Diagnostics Market, by region, 2021 - 2033 (USD Million)
Table 7. Point-of-care Molecular Diagnostics- Key market driver analysis
Table 8. Point-of-care Molecular Diagnostics- Key market restraint analysis
Table 9. North America Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 10. North America Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 11. North America Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 12. North America Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 13. North America Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 14. U.S. Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 15. U.S. Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 16. U.S. Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 17. U.S. Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 18. Canada Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 19. Canada Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 20. Canada Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 21. Canada Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 22. Mexico Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 23. Mexico Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 24. Mexico Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 25. Mexico Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 26. Europe Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 27. Europe Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 28. Europe Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 29. Europe Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 30. Europe Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 31. Germany Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 32. Germany Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 33. Germany Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 34. Germany Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 35. UK Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 36. UK Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 37. UK Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 38. UK Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 39. France Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 40. France Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 41. France Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 42. France Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 43. Italy Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 44. Italy Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 45. Italy Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 46. Italy Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 47. Spain Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 48. Spain Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 49. Spain Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 50. Spain Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 51. Denmark Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 52. Denmark Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 53. Denmark Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 54. Denmark Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 55. Sweden Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 56. Sweden Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 57. Sweden Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 58. Sweden Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 59. Norway Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 60. Norway Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 61. Norway Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 62. Norway Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 63. Asia Pacific Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 64. Asia Pacific Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 65. Asia Pacific Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 66. Asia Pacific Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 67. Asia Pacific Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 68. Japan Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 69. Japan Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 70. Japan Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 71. Japan Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 72. China Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 73. China Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 74. China Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 75. China Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 76. India Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 77. India Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 78. India Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 79. India Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 80. Australia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 81. Australia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 82. Australia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 83. Australia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 84. South Korea Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 85. South Korea Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 86. South Korea Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 87. South Korea Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 88. Thailand Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 89. Thailand Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 90. Thailand Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 91. Thailand Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 92. Latin America Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 93. Latin America Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 94. Latin America Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 95. Latin America Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 96. Latin America Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 97. Brazil Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 98. Brazil Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 99. Brazil Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 100. Brazil Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 101. Argentina Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 102. Argentina Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 103. Argentina Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 104. Argentina Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 105. MEA Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 106. MEA Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 107. MEA Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 108. MEA Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 109. MEA Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 110. South Africa Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 111. South Africa Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 112. South Africa Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 113. South Africa Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 114. Saudi Arabia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 115. Saudi Arabia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 116. Saudi Arabia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 117. Saudi Arabia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 118. UAE Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 119. UAE Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 120. UAE Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 121. UAE Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
Table 122. Kuwait Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
Table 123. Kuwait Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
Table 124. Kuwait Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
Table 125. Kuwait Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Point-Of-Care Molecular Diagnostics Market Segmentation
Fig. 2 Global Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 3 Point-Of-Care Molecular Diagnostics Market Dynamics
Fig. 4 Key Opportunities Prioritized, 2018
Fig. 5 Point-Of-Care Molecular Diagnostics Market - Porter's Analysis
Fig. 6 Point-Of-Care Molecular Diagnostics Market - PESTEL Analysis
Fig. 7 Point-Of-Care Molecular Diagnostics Revenue Share, By Application, 2024 & 2033
Fig. 8 POC Mdx Infectious Diseases Market, 2021 - 2033 (USD Million)
Fig. 9 POC Mdx Oncology Market, 2021 - 2033 (USD Million)
Fig. 10 POC Mdx Hematology Market, 2021 - 2033 (USD Million)
Fig. 11 POC Mdx Prenatal Testing Market, 2021 - 2033 (USD Million)
Fig. 12 POC Mdx Endocrinology Market, 2021 - 2033 (USD Million)
Fig. 13 POC Mdx Other Applications Market, 2021 - 2033 (USD Million)
Fig. 14 Point-Of-Care Molecular Diagnostics Revenue Share, By Technology, 2024 & 2033
Fig. 15 POC Mdx PCR-Based Market, 2021 - 2033 (USD Million)
Fig. 16 POC Mdx Genetic Sequencing-Based Market, 2021 - 2033 (USD Million)
Fig. 17 POC Mdx Hybridization-Based Market, 2021 - 2033 (USD Million)
Fig. 18 POC Mdx Microarray-Based Market, 2021 - 2033 (USD Million)
Fig. 19 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2024 & 2033
Fig. 20 POC Mdx Over-The-Counter Market, 2021 - 2033 (USD Million)
Fig. 21 POC Mdx Point-Of-Care Market, 2021 - 2033 (USD Million)
Fig. 22 Point-Of-Care Molecular Diagnostics Revenue Share, By End Use, 2024 & 2033
Fig. 23 POC Mdx Decentralized Labs Market, 2021 - 2033 (USD Million)
Fig. 24 POC Mdx Hospitals Market, 2021 - 2033 (USD Million)
Fig. 25 POC Mdx Home-Care Market, 2021 - 2033 (USD Million)
Fig. 26 POC Mdx Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
Fig. 27 POC Mdx Other Uses Market, 2021 - 2033 (USD Million)
Fig. 28 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2024 & 2033
Fig. 29 POC Mdx OTC Market, 2021 - 2033 (USD Million)
Fig. 30 POC Mdx POC Market, 2021 - 2033 (USD Million)
Fig. 31 Point-Of-Care Molecular Diagnostics Revenue Share, By Region, 2024 & 2033
Fig. 32 North America Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 33 US Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 34 Canada Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 35 Mexico Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 36 Europe Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 37 Germany Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 38 UK Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 39 France Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 40 Italy Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 41 Spain Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 42 Denmark Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 43 Sweden Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 44 Norway Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 45 Asia Pacific Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 46 Japan Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 47 China Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 48 India Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 49 Australia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 50 South Korea Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 51 Thailand Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 52 Latin America Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 53 Brazil Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 54 Argentina Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 55 MEA Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 56 South Africa Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 57 Saudi Arabia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 58 UAE Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
Fig. 59 Kuwait Point-Of-Care Molecular Diagnostics Market, 2021 - 2033(USD Million)

Product Code: 978-1-68038-886-2

Point-of-Care Molecular Diagnostics Market Summary

The global point of care molecular diagnostics market size was estimated at USD 8.22 billion in 2024 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. This market focuses on rapid and accurate molecular testing conducted near the patient, enabling timely clinical decision-making. These platforms are used across various applications, particularly in infectious disease detection, respiratory illnesses, and sexually transmitted infections.

Market growth is driven by the rising demand for decentralized testing, especially in resource-limited settings and emergency care environments. The increasing burden of infectious diseases and the need for rapid turnaround time have expanded the adoption of point-of-care molecular technologies. Technological advances in microfluidics, isothermal amplification, and portable PCR systems are enhancing the accuracy and usability of these diagnostics. In addition, post-pandemic healthcare priorities emphasize rapid response testing, further supporting market expansion.

Moreover, POC molecular diagnostics in primary care settings range from simple glucose testing to complex coagulation testing. In several clinics, professionals are switching to POC testing from conventional lab testing, which helps shorten the time taken to decide whether further tests are required by avoiding delays during specimen preparation and transport. Other advantages of POC molecular diagnostics are rapid availability of results, lower costs, and better outcomes. The point of care molecular diagnostics industry has grown rapidly in the past few years, especially in the U.S. and European countries, owing to increased awareness regarding various issues such as medical & organizational concerns and economic advantages of POCT.

Aging is influenced by the interaction of several environmental and genetic factors and is characterized as the single most substantial risk factor for cancer development. Based on the U.S. National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in people aged 65 and above, which highlights that aging can make people more vulnerable to cancer. This is where molecular diagnostics play an important role, as it has a tremendous impact on the management of cancer, infectious diseases, and cardiovascular diseases. It is, therefore, vital for public health surveillance and detection. Thus, the growing geriatric population is expected to drive market growth.

Moreover, market players are continuously involved in the development of novel POC testing products to capitalize on market opportunities. For instance, in February 2023, Huwel Lifesciences designed a portable RT-PCR machine to test types of viruses. The company claimed that the test takes around 30 minutes and can be used to detect respiratory and other infections using blood and gastrointestinal samples. Moreover, in April 2023, Curative, Inc. announced the spin-off of Sensible Diagnostics, focusing on the commercialization of a novel POC PCR testing platform to provide results within 10 minutes with high accuracy.

Global Point Of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global point of care molecular diagnostics market report based on application, technology, test location, end-use, and region:

Technology Outlook (Revenue, USD Million, 2021 - 2033)
PCR-based
Genetic Sequencing-based
Hybridization-based
Microarray-based
Application Outlook (Revenue, USD Million, 2021 - 2033)
Infectious Diseases
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV POC
- Other Infectious Diseases
Oncology
Hematology
Prenatal Testing
Endocrinology
Other Applications
Test Location Outlook (Revenue, USD Million, 2021 - 2033)
OTC
POC
End-use Outlook (Revenue, USD Million, 2021 - 2033)
Decentralized Labs
Hospitals
Home-care
Assisted Living Healthcare Facilities
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation
- 1.1.1. Market Definitions
1.2. Objectives
- 1.2.1. Objective - 1
- 1.2.2. Objective - 2
- 1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
- 3.4.1. Growing Demand for Rapid and Decentralized Testing
- 3.4.2. Rising Prevalence of Infectious Diseases
- 3.4.3. Technological Advancements in Molecular Platforms
3.5. Market Restraint Analysis
- 3.5.1. High Cost of Molecular POC Devices and Consumables
- 3.5.2. Regulatory and Quality Assurance Challenges
3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
- 3.6.2. Porter's Five Forces Analysis
- 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
4.2. PCR-based
- 4.2.1. PCR-based Market, 2021 - 2033 (USD Million)
4.3. Genetic Sequencing-based
- 4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Million)
4.4. Hybridization-based
- 4.4.1. Hybridization-based Market, 2021 - 2033 (USD Million)
4.5. Microarray-based
- 4.5.1. Microarray-based Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
5.2. Infectious Diseases
- 5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
- 5.2.2. HIV POC
  - 5.2.2.1. HIV POC Market, 2021 - 2033 (USD Million)
- 5.2.3. Clostridium difficile POC
  - 5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Million)
- 5.2.4. HBV POC
  - 5.2.4.1. HBV POC Market, 2021 - 2033 (USD Million)
- 5.2.5. Pneumonia or Streptococcus associated infections
  - 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Million)
- 5.2.6. Respiratory Syncytial Virus (RSV) POC
  - 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Million)
- 5.2.7. HPV POC
  - 5.2.7.1. HPV POC Market, 2021 - 2033 (USD Million)
- 5.2.8. Influenza/Flu POC
  - 5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Million)
- 5.2.9. HCV POC
  - 5.2.9.1. HCV POC Market, 2021 - 2033 (USD Million)
- 5.2.10. MRSA POC
  - 5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Million)
- 5.2.11. TB and drug-resistant TB POC
  - 5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Million)
- 5.2.12. HSV POC
  - 5.2.12.1. HSV POC Market, 2021 - 2033 (USD Million)
- 5.2.13. Other Infectious Diseases
  - 5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Million)
5.3. Oncology
- 5.3.1. Oncology Market, 2021 - 2033 (USD Million)
5.4. Hematology
- 5.4.1. Hematology Market, 2021 - 2033 (USD Million)
5.5. Prenatal Testing
- 5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Million)
5.6. Endocrinology
- 5.6.1. Endocrinology Market, 2021 - 2033 (USD Million)
5.7. Others
- 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
6.2. OTC
- 6.2.1. OTC Market, 2021 - 2033 (USD Million)
6.3. POC
- 6.3.1. POC Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
7.2. Decentralized Labs
- 7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Million)
7.3. Hospitals
- 7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
7.4. Homecare
- 7.4.1. Home-care Market, 2021 - 2033 (USD Million)
7.5. Assisted Living Healthcare Facilities
- 7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2024 & 2033
8.2. North America
- 8.2.1. North America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.2. U.S.
  - 8.2.2.1. Key Country Dynamics
  - 8.2.2.2. Target Disease Prevalence
  - 8.2.2.3. Competitive Scenario
  - 8.2.2.4. Regulatory Framework
  - 8.2.2.5. Reimbursement Scenario
  - 8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD MILLION)
- 8.2.3. Canada
  - 8.2.3.1. Key Country Dynamics
  - 8.2.3.2. Target Disease Prevalence
  - 8.2.3.3. Competitive Scenario
  - 8.2.3.4. Regulatory Framework
  - 8.2.3.5. Reimbursement Scenario
  - 8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.2.4. Mexico
  - 8.2.4.1. Key Country Dynamics
  - 8.2.4.2. Target Disease Prevalence
  - 8.2.4.3. Competitive Scenario
  - 8.2.4.4. Regulatory Framework
  - 8.2.4.5. Reimbursement Scenario
  - 8.2.4.6. Mexico Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.3. Europe
- 8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.2. Germany
  - 8.3.2.1. Key Country Dynamics
  - 8.3.2.2. Target Disease Prevalence
  - 8.3.2.3. Competitive Scenario
  - 8.3.2.4. Regulatory Framework
  - 8.3.2.5. Reimbursement Scenario
  - 8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.3. UK
  - 8.3.3.1. Key Country Dynamics
  - 8.3.3.2. Target Disease Prevalence
  - 8.3.3.3. Competitive Scenario
  - 8.3.3.4. Regulatory Framework
  - 8.3.3.5. Reimbursement Scenario
  - 8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.4. France
  - 8.3.4.1. Key Country Dynamics
  - 8.3.4.2. Target Disease Prevalence
  - 8.3.4.3. Competitive Scenario
  - 8.3.4.4. Regulatory Framework
  - 8.3.4.5. Reimbursement Scenario
  - 8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.5. Italy
  - 8.3.5.1. Key Country Dynamics
  - 8.3.5.2. Target Disease Prevalence
  - 8.3.5.3. Competitive Scenario
  - 8.3.5.4. Regulatory Framework
  - 8.3.5.5. Reimbursement Scenario
  - 8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.6. Spain
  - 8.3.6.1. Key Country Dynamics
  - 8.3.6.2. Target Disease Prevalence
  - 8.3.6.3. Competitive Scenario
  - 8.3.6.4. Regulatory Framework
  - 8.3.6.5. Reimbursement Scenario
  - 8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.7. Denmark
  - 8.3.7.1. Key Country Dynamics
  - 8.3.7.2. Target Disease Prevalence
  - 8.3.7.3. Competitive Scenario
  - 8.3.7.4. Regulatory Framework
  - 8.3.7.5. Reimbursement Scenario
  - 8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.8. Sweden
  - 8.3.8.1. Key Country Dynamics
  - 8.3.8.2. Target Disease Prevalence
  - 8.3.8.3. Competitive Scenario
  - 8.3.8.4. Regulatory Framework
  - 8.3.8.5. Reimbursement Scenario
  - 8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.3.9. Norway
  - 8.3.9.1. Key Country Dynamics
  - 8.3.9.2. Target Disease Prevalence
  - 8.3.9.3. Competitive Scenario
  - 8.3.9.4. Regulatory Framework
  - 8.3.9.5. Reimbursement Scenario
  - 8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.4. Asia Pacific
- 8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.4.2. Japan
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Target Disease Prevalence
  - 8.4.2.3. Competitive Scenario
  - 8.4.2.4. Regulatory Framework
  - 8.4.2.5. Reimbursement Scenario
  - 8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.4.3. China
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Target Disease Prevalence
  - 8.4.3.3. Competitive Scenario
  - 8.4.3.4. Regulatory Framework
  - 8.4.3.5. Reimbursement Scenario
  - 8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.4.4. India
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Target Disease Prevalence
  - 8.4.4.3. Competitive Scenario
  - 8.4.4.4. Regulatory Framework
  - 8.4.4.5. Reimbursement Scenario
  - 8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.4.5. South Korea
  - 8.4.5.1. Key Country Dynamics
  - 8.4.5.2. Target Disease Prevalence
  - 8.4.5.3. Competitive Scenario
  - 8.4.5.4. Regulatory Framework
  - 8.4.5.5. Reimbursement Scenario
  - 8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.4.6. Australia
  - 8.4.6.1. Key Country Dynamics
  - 8.4.6.2. Target Disease Prevalence
  - 8.4.6.3. Competitive Scenario
  - 8.4.6.4. Regulatory Framework
  - 8.4.6.5. Reimbursement Scenario
  - 8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.4.7. Thailand
  - 8.4.7.1. Key Country Dynamics
  - 8.4.7.2. Target Disease Prevalence
  - 8.4.7.3. Competitive Scenario
  - 8.4.7.4. Regulatory Framework
  - 8.4.7.5. Reimbursement Scenario
  - 8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.5. Latin America
- 8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.5.2. Brazil
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Target Disease Prevalence
  - 8.5.2.3. Competitive Scenario
  - 8.5.2.4. Regulatory Framework
  - 8.5.2.5. Reimbursement Scenario
  - 8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.5.3. Argentina
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Target Disease Prevalence
  - 8.5.3.3. Competitive Scenario
  - 8.5.3.4. Regulatory Framework
  - 8.5.3.5. Reimbursement Scenario
  - 8.5.3.6. Argentina Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
8.6. MEA
- 8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.6.2. South Africa
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Target Disease Prevalence
  - 8.6.2.3. Competitive Scenario
  - 8.6.2.4. Regulatory Framework
  - 8.6.2.5. Reimbursement Scenario
  - 8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.6.3. Saudi Arabia
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Target Disease Prevalence
  - 8.6.3.3. Competitive Scenario
  - 8.6.3.4. Regulatory Framework
  - 8.6.3.5. Reimbursement Scenario
  - 8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.6.4. UAE
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Target Disease Prevalence
  - 8.6.4.3. Competitive Scenario
  - 8.6.4.4. Regulatory Framework
  - 8.6.4.5. Reimbursement Scenario
  - 8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
- 8.6.5. Kuwait
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Target Disease Prevalence
  - 8.6.5.3. Competitive Scenario
  - 8.6.5.4. Regulatory Framework
  - 8.6.5.5. Reimbursement Scenario
  - 8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant's overview
9.2. Financial performance
9.3. Participant categorization
- 9.3.1. Market Leaders
- 9.3.2. Point-of-Care Molecular Diagnostics Market Share Analysis, 2023
- 9.3.3. Company Profiles
  - 9.3.3.1. Abbott
    - 9.3.3.1.1. Company Overview
    - 9.3.3.1.2. Financial Performance
    - 9.3.3.1.3. Product Benchmarking
    - 9.3.3.1.4. Strategic Initiatives
  - 9.3.3.2. Bayer AG
    - 9.3.3.2.1. Company Overview
    - 9.3.3.2.2. Financial Performance
    - 9.3.3.2.3. Product Benchmarking
    - 9.3.3.2.4. Strategic Initiatives
  - 9.3.3.3. F. Hoffmann-La Roche AG
    - 9.3.3.3.1. Company Overview
    - 9.3.3.3.2. Financial Performance
    - 9.3.3.3.3. Product Benchmarking
    - 9.3.3.3.4. Strategic Initiatives
  - 9.3.3.4. Nova Biomedical
    - 9.3.3.4.1. Company Overview
    - 9.3.3.4.2. Financial Performance
    - 9.3.3.4.3. Product Benchmarking
    - 9.3.3.4.4. Strategic Initiatives
  - 9.3.3.5. QIAGEN
    - 9.3.3.5.1. Company Overview
    - 9.3.3.5.2. Financial Performance
    - 9.3.3.5.3. Product Benchmarking
    - 9.3.3.5.4. Strategic Initiatives
  - 9.3.3.6. Nipro Diagnostics
    - 9.3.3.6.1. Company Overview
    - 9.3.3.6.2. Financial Performance
    - 9.3.3.6.3. Product Benchmarking
    - 9.3.3.6.4. Strategic Initiatives
  - 9.3.3.7. Danaher
    - 9.3.3.7.1. Company Overview
    - 9.3.3.7.2. Financial Performance
    - 9.3.3.7.3. Product Benchmarking
    - 9.3.3.7.4. Strategic Initiatives
  - 9.3.3.8. Bio-Rad Laboratories, Inc.
    - 9.3.3.8.1. Company Overview
    - 9.3.3.8.2. Financial Performance
    - 9.3.3.8.3. Product Benchmarking
    - 9.3.3.8.4. Strategic Initiatives
  - 9.3.3.9. bioMerieux
    - 9.3.3.9.1. Company Overview
    - 9.3.3.9.2. Financial Performance
    - 9.3.3.9.3. Product Benchmarking
    - 9.3.3.9.4. Strategic Initiatives
  - 9.3.3.10. Agilent Technologies, Inc.
    - 9.3.3.10.1. Company Overview
    - 9.3.3.10.2. Financial Performance
    - 9.3.3.10.3. Product Benchmarking
    - 9.3.3.10.4. Strategic Initiatives
  - 9.3.3.11. Abaxis
    - 9.3.3.11.1. Company Overview
    - 9.3.3.11.2. Financial Performance
    - 9.3.3.11.3. Product Benchmarking
    - 9.3.3.11.4. Strategic Initiatives
  - 9.3.3.12. OraSure Technologies
    - 9.3.3.12.1. Company Overview
    - 9.3.3.12.2. Financial Performance
    - 9.3.3.12.3. Product Benchmarking
    - 9.3.3.12.4. Strategic Initiatives
- 9.3.4. Strategy Mapping
  - 9.3.4.1. Expansion
  - 9.3.4.2. Acquisition
  - 9.3.4.3. Collaborations
  - 9.3.4.4. Disease Type/Drug Class Launch
  - 9.3.4.5. Partnerships
  - 9.3.4.6. Others

ポイントオブケア分子診断市場規模、シェア、動向分析レポート：用途別、技術別、検査場所別、最終用途別、地域別、セグメント予測、2025年～2033年

Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章市場の変数、動向、範囲

第4章技術ビジネス分析

第5章用途ビジネス分析

第6章検査場所ビジネス分析

第7章最終用途ビジネス分析

第8章地域ビジネス分析

第9章競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Technology Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. Test Location Business Analysis

Chapter 7. End Use Business Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

ポイントオブケア分子診断市場規模、シェア、動向分析レポート：用途別、技術別、検査場所別、最終用途別、地域別、セグメント予測、2025年～2033年

Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

第4章 技術ビジネス分析

第5章 用途ビジネス分析

第6章 検査場所ビジネス分析

第7章 最終用途ビジネス分析

第8章 地域ビジネス分析

第9章 競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Technology Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. Test Location Business Analysis

Chapter 7. End Use Business Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章市場の変数、動向、範囲

第4章技術ビジネス分析

第5章用途ビジネス分析

第6章検査場所ビジネス分析

第7章最終用途ビジネス分析

第8章地域ビジネス分析

第9章競合情勢